Date: September 9th-2010
Time: 11am  to 12pm EST


Speakers:

Peter Engardio - Former Business Week Senior Writer and Asia Editor & Book Author
Joins
Rajiv Gulati -
Former Head- Eli Lilly India & China Strategy

It's no secret-the center of gravity for the pharmaceutical industry is shifting to Asia, led by the two developing nations of China and India.

India and China share many similarities as possible partners to Western biopharmaceutical companies & future fast-rising end-markets for new drug sales. But look deep down and you’ll see two very different areas of possible opportunities.

Opportunities in the East notwithstanding, the West needs to prepare for uncertainty by analyzing the complex and not-so-obvious ways global trends interact in their industries.
 
Whether your interest lies with:
> Tapping Asia’s large population pool of treatment naïve patients in China or India
> Learning how a Big Pharma is dealing with anti-counterfeiting measures in these two regions
> Leveraging Low-Cost/High-Skilled scientific labor
> Deploying e-outsourcing partnerships for discovery / R&D, later stage clinical trials or GMP compliant     manufacturing
> Seeking generic drug sources or partner
> Seeking new market opportunities and sources of drugs sales revenues in the future
> Shopping for joint ventures or M&As in Asia

On September 9th , 2010—former Business Week Senior Writer Peter Engardio, author of the highly acclaimed book “Chindia: How China and India Are Revolutionizing Global Business”, joins Rajiv Gulati, former Head of Eli Lilly India/China Strategy & Senior Director of Global AntiCounterfeiting Operations, on a 60-minute webinar to DISSECT “ How China and India Are Changing Global Pharmaceutical Competitiveness: Are you Ready?” 

On this webinar, Peter Engardio will pose probing questions to Rajiv Gulati for Big Pharma’s in-depth, in-the know answers to provocative questions such as: 
  1) “We keep hearing about the 30-60% savings of drug discovery and development work in China and India. Is it really working out that way for MNCs?”

   2) “MNCs seem to be making much bigger investments in captive R&D centers in China than they are in India. Why is that? “

   3) “In most every other industry, intellectual property is a much bigger problem in China than in India. But in pharmaceuticals, it is the other way around. Please explain.”

   4) “How are these risk-sharing partnerships with Indian CROs working out in practice? In general, are they delivering as promised to MNCs? Is the quality of their work as good as advertised? Same question for the Chinese CROs.”

   5) “The health care systems are evolving in both India and China. India is mainly out-of-pocket and is grossly underserved. In China, drugs are distributed through hospitals and cost can be very expensive for the average person. How will these systems evolve, and what does that mean for big pharmaceutical companies?”

   6) “If you aren't doing a lot in India or China now, is it too late? Are is there an advantage in being a late mover?”

   7) More pharma MNCs are turning their attention to "smaller" diseases and niche markets, rather than focusing exclusively on megabillion blockbusters. Will this continue, and are the lower drug discovery costs in China and India helping this trend?

  8) Traditional Chinese Medicine (TCM) in China and ayurvedics in India are big markets.
   Why is  it we see very little interest or developments on this from Big Pharma? Can you explain?


On September 9th -2010, listen to two renowned experts dissect just what is “underneath the hood.”

This webinar will give you a better understanding of what’s the same and what’s different with China and India as both countries change the global pharma competitiveness scenario by addressing:
> Old vs New business models from FIPCO to FIPNET ----  Rajiv Gulati assisted in the implementation of a    successful business model in India for Eli Lilly
> Peter Engardio contrasts China’s and India’s strengths and weaknesses after his travels to both    countries
> Peter probes Rajiv Gulati for  Eli Lilly’s strategies in India and China with regards to
- Pharma market sales growth in both China & India
- Explore vastly different  demographics of China’s aging population vs. India with the    youngest  global pool (40% under 25) 
- Compare unique advantages of the life science talents between the 2 countries
- MNC investments
- Varying business models arising from the different political cultures of democratic India    and the Chinese central government
 
Past Webinar Recording CD are available for purchase
 
For more information contact Ram Balani at 516-515-9642 or email at rbalani@fdasmart.com